Citations

Clear

1526 citation(s) found for "Sun, Yu".

A signature based on costimulatory molecules for the assessment of prognosis and immune characteristics in stomach adenocarcinoma
Chen, Bangjie , Yao, Yong , Mao, Deshen, Li, Conghan, Wang, Xingyu , Sheng, Shuyan , Zhang, Lizhi , Wang, Xinyi , Deng, Jianyi , Bentley, Rachel , Shao, Wei , Li, Conghan, Chen, Sanwei , Xu, Wentao , Sun, Chenyu , Zhou, Qin Yuan , Lowe, Scott W. , Li, Haiwen

Mayo Clinic

No container title available | April 25, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1577855/v1 Get It

Abstract Although costimulatory molecules have been shown to boost antitumor immune responses, their significance in stomach adenocarcinoma (STAD) is unknown. The purpose of this study was to examine the gene expression patterns of costimulatory molecule genes in STAD and to develop a predictive signature to aid in therapy selection and outcome prediction. We used 60 costimulatory family genes from prior research to conduct the first complete costimulatory molecule analysis in STAD patients. For the two groups discovered, consensus clustering analysis based on these 60 genes indicated unique distribution patterns and prognostic differences. Then, using Lasso and Cox regression analysis, 9 costimulatory molecular gene pairs (CMGPs) of prognostic value were discovered. With these 9 CMGPs, we were able to develop a costimulatory molecule-related prognostic signature, which performed well in an external dataset. For STAD patients, the signature was proved to be a risk factor independent of clinical characteristics, indicating that this may be employed in conjunction with clinical considerations. An further connection between the signature and immunotherapy response was discovered. People who had high mutation rates, an abundance of infiltrating immune cells, and an immunosuppressive milieu were classed as high-risk. It is possible that patients classed as high-risk have a better prognosis for immunotherapy since these patients have greater cytolytic activity scores and immunophenoscores of CTLA4 and PD-L1/PD-L2 blocker As a consequence, clinicians might use our signature to better assess patient prognosis and develop treatment plans.
PBX1-SIRT1 positive feedback loop attenuates ROS-mediated HF- MSC senescence and apoptosis
Wang, Yuan , Sui, Yutong , Niu, Ye, Liu, Dan , Xu, Qi , Liu, Feilin , Zuo, Kuiyang , Liu, mingsheng, Sun, Wei , Liu, Zinan , Zou, Fei , Shi, Jiahong , Liu, Xiao mei, Liu, Jinyu , Zuo, Kuiyang , Wang, Ziyu

Mayo Clinic

No container title available | April 15, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.21203/rs.3.rs-1545647/v1 Get It

Abstract Background: Stem cell senescence and depletion are major causes of organismal aging and aging-related diseases. The NAD–SIRT1–PARP1 axis has garnered remarkable interest owing to its significant role in regulating stem cell senescence and organismal aging. Event though our recent study showes that PBX1 overexpression attenuates hair follicle-derived mesenchymal stem cell (HF-MSC) senescence and apoptosis by regulating ROS-mediated DNA damage via downregulation of PARP1 expression, suggesting PARP1 downregulation is a common manifestation of the roles of both PBX1 and SIRT1 in the attenuation of HF-MSC senescence, and implying a potential link between PBX1 and SIRT1 via PARP1. Methods: HF-MSCs overexpressing PBX1, overexpressing both PBX1 and PARP1, downregulating SIRT1, and overexpressing PBX1 and downregulating SIRT1 were generated, and biomarkers related to cell senescence, apoptosis, DNA damage, and repair were detected at the cellular and protein levels. Results: (1) PBX1 overexpression alleviated HF-MSC senescence and apoptosis accompanied by upregulation of SIRT1 expression, downregulation of PARP1 expression, and increased intracellular NAD and ATP levels. (2) SIRT1 knockdown or PARP1 overexpression enhanced cellular senescence and apoptosis, accompanied by increased ROS accumulation and DNA damage aggravation and decreased intracellular NAD and ATP levels. (3) PBX1 overexpression rescued HF-MSC senescence and apoptosis induced by SIRT1 knockdown or PARP1 overexpression. (4) Dual luciferase reporter showed PBX1 enhanced SIRT1 expression by activating SIRT1 promoter. Conclusions: Our results reveal that a positive interaction feedback loop exists between PBX1 and SIRT1, that PBX1 is the upstream of SIRT1. To the best of our knowledge we are the first to report that there is a PBX1-SIRT1-PARP1 axis and this axis plays a critical role in alleviation of HF-MSC senescence and apoptosis. The results provide a new perspective on the mechanism of stem cell senescence and age-related disease prevention and treatment.
Efficacy of laser interstitial thermal therapy (LITT) for newly diagnosed and recurrent IDH wild-type glioblastoma
Prabhu, Sujit S. , Rao, Ganesh , Laxton, Adrian W. , Fecci, Peter E. , O’Brien, Barbara , Sloan, Andrew E. , Chiang, Veronica , Mohammadi, Alireza M. , Chen, Clark, Sun, David, Sinicrope, Kaylyn, Campian, Jian , Kurz, Sylvia C. , Smith, Kris A. , Tovar-Spinoza, Zulma , Leuthardt, Eric C. , Khasraw, Mustafa , Fecci, Peter E , Groot, John de , Kim, Albert H. , Tatter, Stephen B. , Placantonakis, Dimitris G. , Strowd, Roy E. , Hadjipanayis, Costas G. , Khasraw, Mustafa , Piccioni, David Eric , Williams, Brian J.

Mayo Clinic

Neuro-Oncology Advances | April 6, 2022 | Volume: 4 | Issue: 1 | Pages: No page available

10.1093/noajnl/vdac040 | PMID 35611270 Get It

Abstract Background Treatment options for unresectable new and recurrent glioblastoma remain limited. Laser ablation has demonstrated safety as a surgical approach to treating primary brain tumors. The LAANTERN prospective multicenter registry (NCT02392078) data were analyzed to determine clinical outcomes for patients with new and recurrent IDH wild-type glioblastoma. Methods Demographics, intraprocedural data, adverse events, KPS, health economics, and survival data were prospectively collected and then analyzed on IDH wild-type newly diagnosed and recurrent glioblastoma patients who were treated with laser ablation at 14 US centers between January 2016 and May 2019. Data were monitored for accuracy. Statistical analysis included individual variable summaries, multivariable differences in survival, and median survival numbers. Results A total of 29 new and 60 recurrent IDH wild-type WHO grade 4 glioblastoma patients were treated. Positive MGMT promoter methylation status was present in 5/29 of new and 23/60 of recurrent patients. Median physician-estimated extent of ablation was 91%-99%. Median overall survival (OS) was 9.73 months (95% confidence interval: 5.16, 15.91) for newly diagnosed patients and median post-procedure survival was 8.97 months (6.94, 12.36) for recurrent patients. Median OS for newly diagnosed patients receiving post-LITT chemo/radiation was 16.14 months (6.11, not reached). Factors associated with improved survival were MGMT promoter methylation, adjuvant chemotherapy within 12 weeks, and tumor volume <3 cc. Conclusions Laser ablation is a viable option for patients with new and recurrent glioblastoma. Median OS for IDH wild-type newly diagnosed glioblastoma is comparable to outcomes observed in other tumor resection studies when those patients undergo radiation and chemotherapy following LITT.
Diabetes mellitus in relation to colorectal tumor molecular subtypes: A pooled analysis of more than 9000 cases
Harlid, Sophia , Guelpen, Bethany Van , Gylling, Björn , Aglago, Elom K. , Amitay, Efrat L. , Brenner, Hermann , Buchanan, Daniel D. , Cao, Yin , Chang‐Claude, Jenny , Drew, David A. , Figueiredo, Jane C. , French, Amy J. , Gallinger, Steven , Giannakis, Marios , Hoffmeister, Michael , Newton, Christina C. , Obón‐Santacana, Mireia , Song, Mingyang , Steinfelder, Robert S. , Thibodeau, Stephen N. , Woods, Michael O. , Phipps, Amanda I. , Harrison, Tabitha A. , Peters, Ulrike , Van Guelpen, Bethany , Amitay, Efrat L , Buchanan, Daniel D , Hoffmeister, Michael , Moreno, Victor , Murphy, Neil , Song, Mingyang , Cao, Yin , Drew, David A , Harrison, Tabitha A , Brenner, Hermann , Aglago, Elom K , Obón-Santacana, Mireia , Qu, Conghui , Campbell, Peter T. , Chan, Andrew T. , Giles, Graham G. , Gunter, Marc J. , Jenkins, Mark A. , Lin, Yi , Moreno, Vı́ctor , Murphy, Neil , Newcomb, Polly A. , Nowak, Jonathan A. , Ogino, Shuji , Potter, John D. , Sun, Wei , Toland, Amanda Ewart , Ugai, Tomotaka , Um, Caroline Y.

Mayo Clinic

International Journal of Cancer | April 6, 2022 | Volume: 151 | Issue: 3 | Pages: 348-360

10.1002/ijc.34015 | PMID 35383926 Get It

AbstractDiabetes is an established risk factor for colorectal cancer. However, colorectal cancer is a heterogeneous disease and it is not well understood whether diabetes is more strongly associated with some tumor molecular subtypes than others. A better understanding of the association between diabetes and colorectal cancer according to molecular subtypes could provide important insights into the biology of this association. We used data on lifestyle and clinical characteristics from the Colorectal Cancer Family Registry (CCFR) and the Genetics and Epidemiology of Colorectal Cancer Consortium (GECCO), including 9756 colorectal cancer cases (with tumor marker data) and 9985 controls, to evaluate associations between reported diabetes and risk of colorectal cancer according to molecular subtypes. Tumor markers included BRAF and KRAS mutations, microsatellite instability and CpG island methylator phenotype. In the multinomial logistic regression model, comparing colorectal cancer cases to cancer‐free controls, diabetes was positively associated with colorectal cancer regardless of subtype. The highest OR estimate was found for BRAF‐mutated colorectal cancer, n = 1086 (ORfully adj: 1.67, 95% confidence intervals [CI]: 1.36‐2.05), with an attenuated association observed between diabetes and colorectal cancer without BRAF‐mutations, n = 7959 (ORfully adj: 1.33, 95% CI: 1.19‐1.48). In the case only analysis, BRAF‐mutation was differentially associated with diabetes (Pdifference = .03). For the other markers, associations with diabetes were similar across tumor subtypes. In conclusion, our study confirms the established association between diabetes and colorectal cancer risk, and suggests that it particularly increases the risk of BRAF‐mutated tumors.
Implications of sympathetic activation for objective versus self-reported daytime sleepiness in obstructive sleep apnea
Chen, Baixin , Sun, Qimeng, Dai, Yanyuan , Li, Yun , Somers, Virend K.

Mayo Clinic

Sleep | April 4, 2022 | Volume: 45 | Issue: 7 | Pages: No page available

10.1093/sleep/zsac076 | PMID 35373304 Get It

Abstract Study Objectives Objective excessive daytime sleepiness (EDS) is associated with systemic inflammation and a higher risk of cardiometabolic morbidity in obstructive sleep apnea (OSA). We hypothesized that OSA with objective EDS is associated with higher levels of sympathetic nerve activity (SNA) when compared with self-reported EDS. We, therefore, examined the associations between objective and self-reported EDS with SNA in patients with OSA. Methods We studied 147 consecutive male patients with OSA from the institutional sleep clinic. Objective EDS and self-reported EDS were defined based on Multiple Sleep Latency Test (MSLT) latency ≤ 8 minutes and Epworth Sleepiness Scale (ESS) > 10, respectively. Twenty-four-hour urinary norepinephrine was used for assessing SNA. Blood pressure (BP) was measured both in the evening and in the morning. Results Twenty-four-hour urinary norepinephrine was significantly higher in patients with OSA with objective EDS compared with those without objective EDS (p = 0.034), whereas it was lower in patients with OSA with self-reported EDS compared with those without self-reported EDS (p = 0.038) after adjusting for confounders. Differences in the sympathetic drive were most striking in those with an objective but not self-reported EDS versus those with self-reported but not objective EDS (p = 0.002). Moreover, shorter MSLT latency was significantly associated with higher diastolic BP (β = −0.156, p = 0.049) but not systolic BP. No significant association between ESS scores and BP was observed. Conclusions Objective, but not self-reported EDS, is associated with increased SNA and diastolic BP among males with OSA, suggesting that objective EDS is a more severe phenotype of OSA that is accompanied by higher sympathetic drive, higher BP, and possibly greater cardiovascular morbidity and mortality.
Perspective: Pivotal translational hematology and therapeutic insights in chronic myeloid hematopoietic stem cell malignancies
Mughal, Tariq I. , Pemmaraju, Naveen , Royston, Daniel , Valent, Peter , Patnaik, Mrinal M. , Fenaux, Pierre , Verstovšek, Srđan , Barbui, Tiziano , Etten, Richard A. Van , Verstovsek, Srdan , Valent, Peter , Bejar, Rafael , Gale, Robert Peter , Bose, Prithviraj , Kiladjian, Jean‐Jacques , Prchal, Josef T. , Pollyea, Daniel Aaron , Brümmendorf, Tim H. , Skórski, Tomasz , Santini, Valeria , Kucine, Nicole , Mesa, Ruben A. , Saglio, Giuseppe

Mayo Clinic

Hematological Oncology | April 3, 2022 | Volume: 40 | Issue: 4 | Pages: 491-504

10.1002/hon.2987 | PMID 35368098 Get It

Abstract Despite much of the past 2 years being engulfed by the devastating consequences of the SAR‐CoV‐2 pandemic, significant progress, even breathtaking, occurred in the field of chronic myeloid malignancies. Some of this was show‐cased at the 15th Post‐American Society of Hematology (ASH) and the 25th John Goldman workshops on myeloproliferative neoplasms (MPN) held on 9th‐10th December 2020 and 7th‐10th October 2021, respectively. The inaugural Post‐ASH MPN workshop was set out in 2006 by John Goldman (deceased) and Tariq Mughal to answer emerging translational hematology and therapeutics of patients with these malignancies. Rather than present a resume of the discussions, this perspective focuses on some of the pivotal translational hematology and therapeutic insights in these diseases.
Consensus subtypes of hepatocellular carcinoma associated with clinical outcomes and genomic phenotypes
Lee, Sung Hwan , Yim, Sun Young , Jeong, Yun Seong , Li, Qi‐Xiang, Kang, Sanghee , Sohn, Bo Hwa, Kumar, Shwetha V. , Shin, Ji‐Hyun , Choi, You Rhee, Kim, Hayeon , Kim, Ji Hoon , Kim, Shin , Guo, Sheng , Johnson, Randy L. , Kang, Koo Jeong , Chun, Yun Shin , Jang, Hee Jin, Lee, Byoung Gill, Woo, Hyun Goo , Akbani, Rehan , Roberts, Lewis R. , Wheeler, David A. , Kang, Sang-Hee , Kim, Ji Hoon , Ha, Min Jin , Roberts, Lewis R , Shim, Jae‐Jun , Kaseb, Ahmed O , Lee, Ju‐Seog

Mayo Clinic

Hepatology | March 29, 2022 | Volume: 76 | Issue: 6 | Pages: 1634-1648

10.1002/hep.32490 | PMID 35349735 Get It

Abstract Background and Aims Although many studies revealed transcriptomic subtypes of HCC, concordance of the subtypes are not fully examined. We aim to examine a consensus of transcriptomic subtypes and correlate them with clinical outcomes. Approach and Results By integrating 16 previously established genomic signatures for HCC subtypes, we identified five clinically and molecularly distinct consensus subtypes. STM (STeM) is characterized by high stem cell features, vascular invasion, and poor prognosis. CIN (Chromosomal INstability) has moderate stem cell features, but high genomic instability and low immune activity. IMH (IMmune High) is characterized by high immune activity. BCM (Beta‐Catenin with high Male predominance) is characterized by prominent β‐catenin activation, low miRNA expression, hypomethylation, and high sensitivity to sorafenib. DLP (Differentiated and Low Proliferation) is differentiated with high hepatocyte nuclear factor 4A activity. We also developed and validated a robust predictor of consensus subtype with 100 genes and demonstrated that five subtypes were well conserved in patient‐derived xenograft models and cell lines. By analyzing serum proteomic data from the same patients, we further identified potential serum biomarkers that can stratify patients into subtypes. Conclusions Five HCC subtypes are correlated with genomic phenotypes and clinical outcomes and highly conserved in preclinical models, providing a framework for selecting the most appropriate models for preclinical studies.
To Withdraw or to Continue ICU Care: When Is it a Premature Question?*
Athale, Janhavi, Grazioli, Alison , Sun, Junfeng

Mayo Clinic

Critical Care Medicine | March 21, 2022 | Volume: 50 | Issue: 4 | Pages: 693-695

10.1097/ccm.0000000000005349 | PMID 35311778 Get It

Author response: Binding blockade between TLN1 and integrin β1 represses triple-negative breast cancer
Zhang, Yixiao , Sun, Lisha , Ai, Liping, Ma, Qingtian, Qiao, Xinbo , Yang, Jie , Zhang, Hao , Ou, Xunyan, Chen, Guanglei , Xue, Jinqi , Zhao, Yu , Yang, Yongliang , Liu, Caigang , Li, Haonan , Wang, Yining , Zhu, Xudong , Liu, Caigang

Mayo Clinic

No container title available | March 21, 2022 | Volume: No volume available | Issue: No issue available | Pages: No page available

10.7554/elife.68481.sa2 Get It